Omnipod 5 Waterproof Automated Insulin Delivery System User Guide

June 12, 2024
omnipod

Omnipod 5 Waterproof Automated Insulin Delivery System User Guide

Omnipod 5 Waterproof Automated Insulin Delivery
System.jpg

Pod and Dexcom G6 shown without necessary adhesive. Dexcom G6 sold separately and requires a separate prescription.

Helpful tips to talk to your doctor about Omnipod 5
Omnipod 5 is the first and only tubeless, waterproof* automated insulin delivery system in the US. It automatically adjusts insulin delivery to manage blood glucose values day and night.

Deciding on the right diabetes therapy can be a big decision, and you don’t have to make it alone. Use this guide to have a discussion with your healthcare provider to determine if Omnipod 5 might be right for you.

Feel free to print it and bring it to your next appointment or send it to your healthcare provider in advance.

FIG 1.JPG

Still have questions?
Our Omnipod Specialists are here to help. Call them today at 1-800-591-9948.

  • The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller and Personal Diabetes Manager (PDM) are not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under eight feet of water for up to 24 hours without failure when properly installed.

† For a list of compatible smartphone devices visit omnipod.com/compatibility

  1. Study in 240 people with T1D aged 6 – 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/ adolescents and children, standard therapy vs. 3-mo Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et al. Diabetes Care (2021).
  2. Study in 80 people with T1D aged 2 – 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose (>180mg/dL) from CGM in standard therapy vs Omnipod 5 = 39.4% vs. 29.5%. Average time with low blood glucose (<70mg/dL) from CGM in standard therapy vs Omnipod 5 = 3.41% vs. 2.13%. Sherr JL, et al. Diabetes Care (2022).
  3. Study in 128 people with T1D aged 14 – 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents = 64.7% vs. 73.9%. Brown et al. Diabetes Care (2021).
  4. Study in 112 people with T1D aged 6 – 13.9 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in children = 52.5% vs 68.0%. Brown S. et al. Diabetes Care (2021).
  5. Study in 80 people with T1D aged 2 – 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (12AM -< 6AM) from CGM in standard therapy vs. Omnipod 5 = 58.2% vs 81.0%. Sherr JL, et al. Diabetes Care (2022).

FIG 2.JPG

Here is some useful information when filling an Omnipod 5 prescription.

Omnipod has partnered with ASPN Pharmacies who will coordinate the fulfillment with your patient at their pharmacy of choice. When e-prescribing please submit prescriptions to ASPN Pharmacies.

FIG 3.JPG

Office Staff Note: Once supplies are received, patients can visit omnipod.com/setup to begin device setup and schedule their training.

An Omnipod Pharmacy Specialist is available to help you and your office staff with PAs or appeals, if needed.
To contact a Specialist, call 1-866-347-0036

Insulet • 100 Nagog Park, Acton, MA 01720 • 1-800-591-3455 • omnipod.com
6. Study in 80 people with T1D aged 2 – 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (12AM -< 6AM) from CGM in standard therapy vs. Omnipod 5 = 58.2% vs 81.0%. Sherr JL, et al. Diabetes Care (2022).
7. Study in 128 people with T1D aged 14 – 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Median time with low blood glucose (from CGM) for standard therapy vs Omnipod 5 = 2.00% vs 1.09%. Brown S. et al. Diabetes Care (2021).
8. Study in 240 people with T1D aged 6 – 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average A1c in adults/adolescents and children, standard therapy vs. Omnipod 5 = 7.16% vs 6.78%; 7.67% vs 6.99%. Brown S. et al. Diabetes Care (2021).
§ Clinical rationale must be provided for Pod changes that occur more frequently than 72 hrs.
©2023 Insulet Corporation. Omnipod, the Omnipod logo, and Simplify Life are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation. INS-OHS-11-2022-00061 v1.0

Read More About This Manual & Download PDF:

References

Read User Manual Online (PDF format)

Read User Manual Online (PDF format)  >>

Download This Manual (PDF format)

Download this manual  >>

Related Manuals